- Conditions
- Prostate Cancer
- Interventions
- Abiraterone acetate
- Drug
- Lead sponsor
- Cougar Biotechnology, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 64
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- High-Risk Prostate Cancer
- Interventions
- Capivasertib, abiraterone acetate
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
- Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Interventions
- PF-06821497, Docetaxel, Enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 70
- States / cities
- Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
- Interventions
- cabozantinib, atezolizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 57
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
- Conditions
- Prostate Cancer
- Interventions
- GnRH, Bicalutamide, Salvage radiation, Abiraterone, Prednisone, Apalutamide
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 95 Years · Male only
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 8
- States / cities
- San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, Abiraterone, Leuprolide, stereotactic, ultra-fractionated radiotherapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 11
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Middletown, New Jersey + 7 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more
- Conditions
- Castrate-resistant Prostate Cancer
- Interventions
- BEZ235, Prednisone, Abiraterone acetate
- Drug
- Lead sponsor
- Charles Ryan
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Abiraterone acetate, Prednisone, Placebo
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 982 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more
- Conditions
- Prostate Cancer
- Interventions
- Ipilimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 3
- States / cities
- Evanston, Illinois • New York, New York • Portland, Oregon
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- Interventions
- Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 63
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Abiraterone acetate
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
- Conditions
- Prostate Cancer
- Interventions
- Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts
- Conditions
- Progressive Metastatic Castrate-Resistant Prostate Cancer
- Interventions
- AZD4635, Durvalumab, Cabazitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Detroit, Michigan • Syracuse, New York • Myrtle Beach, South Carolina + 1 more
- Conditions
- Prostate Cancer, Localized Prostate Cancer
- Interventions
- Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix
- Drug
- Lead sponsor
- Kenneth Pienta, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Abemaciclib, Placebo, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 20 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
- Combination Product · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 53
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- ARX517, Apalutamide, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone acetate, Androgen deprivation, Radiation Therapy, Prednisone
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Houston, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 29
- States / cities
- Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 14
- States / cities
- Muscle Shoals, Alabama • Anchorage, Alaska • Anaheim, California + 11 more